Skip to main content
Benjamin Neel, MD, Internal Medicine, Boston, MA

Benjamin Gilbert Neel MD


Director, Laura and Isaac Perlmutter Cancer Center

Join to view full profile
  • 77 Avenue Louis Pasteur# NrbBoston, MA 02115

  • Phone+1 617-667-2823

  • Fax+1 212-263-9190

Dr. Neel is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1983 - 1987
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1983

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1984 - 2028

Publications & Presentations

PubMed

Journal Articles

  • The Gp1ba-Cre Transgenic Mouse: A New Model to Delineate Platelet and Leukocyte Functions  
    Benjamin Neel, MD, Blood

Press Mentions

  • NYU Grossman Rescinds Program Acceptances After Losing Federal Grant
    NYU Grossman Rescinds Program Acceptances After Losing Federal GrantMay 14th, 2025
  • MSK Research Highlights, January 17, 2025
    MSK Research Highlights, January 17, 2025January 17th, 2025
  • NYU Langone Health’s Perlmutter Cancer Center Continues to Grow in Brooklyn, Provide Care to Diverse Populations
    NYU Langone Health’s Perlmutter Cancer Center Continues to Grow in Brooklyn, Provide Care to Diverse PopulationsApril 5th, 2023

Grant Support

  • SHP2 Signaling from Molecule to MouseNEW YORK UNIVERSITY SCHOOL OF MEDICINE2026–2031
  • Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancerNEW YORK UNIVERSITY SCHOOL OF MEDICINE2025–2027
  • Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1NEW YORK UNIVERSITY SCHOOL OF MEDICINE2022–2026
  • Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1NEW YORK UNIVERSITY SCHOOL OF MEDICINE2022–2026
  • New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian CarcinomaNEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2025

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: